News

Anatomy of a molecule:
What makes remdesivir unique?

Experts weigh in on the chemistry of the potential SARS-nCoV-2 antiviral
Laurel Oldach
March 17, 2020

The World Health Organization in late January convened experts to discuss experimental therapeutics for patients with the emerging coronavirus with no name, no vaccine and no treatment. The panel reported that “among the different therapeutic options, remdesivir was considered the most promising candidate.”

Within weeks, a clinical trial of the compound was underway in China. Results are expected in April; in the meantime, the outbreak of SARS-nCoV-2, the virus that causes COVID-19, has become a global pandemic.

Remdesivir is a nucleoside analog, one of the oldest classes of antiviral drugs. It works by blocking the RNA polymerase that coronaviruses and related RNA viruses need to replicate their genomes and proliferate in the host body.

The molecule originally was synthesized as part of a screen for inhibitors of the hepatitis C virus RNA polymerase. Its inventors at Gilead Sciences decided to move forward with a different nucleoside analog compound to treat hepatitis C. But RNA-dependent RNA polymerases are conserved between many viruses. Experiments in vitro, in cell culture and in animal models have shown that remdesivir has broad-spectrum activity against RNA viruses, including filoviruses (like the one that causes Ebola) and coronaviruses.

Remdesivir resembles the RNA base adenosine, shown here as a monophosphate.

AMP.jpg

The compound and ATP have some important differences, but some features are very similar. ASBMB Today spoke to medicinal chemist Katherine Seley–Radtke at the University of Maryland, Baltimore County, and structural virologist Craig Cameron at the University of North Carolina, Chapel Hill about what makes the molecule interesting. Click on a feature marked in blue to read their remarks.

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Sphingolipids show potential as biomarkers for multiple sclerosis
Journal News

Sphingolipids show potential as biomarkers for multiple sclerosis

December 01, 2020

Maria Podbielska and colleagues at the Hirszfeld Institute write in the Journal of Lipid Research about their finding that ceramide levels vary in active and inactive MS lesions in the nervous system.

World AIDS Day 2020
Health Observance

World AIDS Day 2020

December 01, 2020

Despite decades of research and amazing scientific advancements, HIV remains a global threat.

Will the coronavirus evolve to be less deadly?
News

Will the coronavirus evolve to be less deadly?

November 29, 2020

All pandemics eventually run their course. But history and science suggest many possible pathways. How might COVID-19 end?

Uncovering details of molecular Ferris wheels inside cell structures
News

Uncovering details of molecular Ferris wheels inside cell structures

November 28, 2020

Simulations on the nation’s fastest supercomputer confirm details of a molecular mechanism that cell organelles use to regulate the pH of their environment.

The NIH is turning the human reference genome into a pangenome
News

The NIH is turning the human reference genome into a pangenome

November 26, 2020

In 2000, the human genome was announced as completed. But it was filled with gaps, and did not represent humanity’s genetic diversity. Read and watch a short film about recent updates.

From the journals: MCP
Journal News

From the journals: MCP

November 25, 2020

A destructive disease can lurk in a citrus plant’s vascular system. Misfolded proteins offer a key to inflammation in liver disease. And proteomic studies provide clues about signaling linked to neurological disorders.